In 2018 NICE is due to commence the review of this guidance, to register as a stakeholder please contact us at email@example.com
NICE has developed medical technology guidance on Virtual Touch Quantification (VTq).
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
VTq should be considered as an option for people with chronic hepatitis B or C who need assessment of liver fibrosis.
VTq is as accurate as transient elastography in diagnosing and staging liver fibrosis, and may offer other benefits in terms of imaging the liver and sampling selected areas. By avoiding liver biopsies, it may also benefit people whose liver fibrosis needs monitoring.
Cost modelling suggests that VTq is cost saving compared with transient elastography and liver biopsy, whether or not a compatible Siemens ultrasound machine needs to be purchased.